Induction of Brain Microvascular Endothelial Cell Urokinase Expression by Cryptococcus neoformans Facilitates Blood-Brain Barrier Invasion

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Stie, Jamal ^a   Fox, Deborah ^a,b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLASMINOGEN; SMALL INTERFERING RNA; UROKINASE;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; ENZYME ACTIVITY; ENZYME INDUCTION; FUNGAL CELL CULTURE; FUNGAL GENE; FUNGAL STRAIN; GENE EXPRESSION REGULATION; GENE SILENCING; MICROVASCULAR ENDOTHELIAL CELL; MICROVASCULARIZATION; MOLECULAR INTERACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PLASMINOGEN ACTIVATION; PROTEIN EXPRESSION; SPECIES INVASION; TRANSCRIPTION REGULATION; UROKINASE GENE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CATTLE; COCULTURE TECHNIQUES; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; PLASMINOGEN; RNA INTERFERENCE; RNA, MESSENGER; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VIRULENCE;

BOVINAE; FILOBASIDIELLA NEOFORMANS;

EID: 84869035223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049402     Document Type: Article

References (87)

1. Bennett JE, Kwon-Chung KJ, Howard DH, (1977) Epidemiologic differences among serotypes of Cryptococcus neoformans. Am J Epidemiol 105: 582-586.
2. Kwon-Chung KJ, Bennett JE, (1984) Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 120: 123-130.
3. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
4. Velagapudi R, Hsueh YP, Geunes-Boyer S, Wright JR, Heitman J, (2009) Spores as infectious propagules of Cryptococcus neoformans. Infect Immun 77: 4345-4355.
5. Powderly WG, (1993) Cryptococcal meningitis and AIDS. Clin Infect Dis 17: 837-842.
6. Huffnagle GB, Yates JL, Lipscomb MF, (1991) Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J Exp Med 173: 793-800.
7. Casadevall A, (2010) Cryptococci at the brain gate: break and enter or use a Trojan horse? J Clin Invest 120: 1389-1392.
8. Ma H, Croudace JE, Lammas DA, May RC, (2006) Expulsion of live pathogenic yeast by macrophages. Curr Biol 16: 2156-2160.
9. Huang SH, Long M, Wu CH, Kwon-Chung KJ, Chang YC, et al. (2011) Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3). J Biol Chem 286: 34761-34769.
10. Jong A, Wu CH, Prasadarao NV, Kwon-Chung KJ, Chang YC, et al. (2008) Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells requires protein kinase C-alpha activation. Cell Microbiol 10: 1854-1865.
11. Jong A, Wu CH, Shackleford GM, Kwon-Chung KJ, Chang YC, et al. (2008) Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell Microbiol 10: 1313-1326.
12. Long M, Huang SH, Wu CH, Shackleford GM, Jong A, (2012) Lipid raft/caveolae signaling is required for Cryptococcus neoformans invasion into human brain microvascular endothelial cells. J Biomed Sci 19: 19.
13. Chen SH, Stins MF, Huang SH, Chen YH, Kwon-Chung KJ, et al. (2003) Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J Med Microbiol 52: 961-970.
14. Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, et al. (2004) Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun 72: 4985-4995.
15. Jong A, Wu CH, Chen HM, Luo F, Kwon-Chung KJ, et al. (2007) Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection. Eukaryot Cell 6: 1486-1496.
16. Chang YC, Kwon-Chung KJ, (1994) Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 14: 4912-4919.
17. Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, et al. (2005) Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol 166: 421-432.
18. Shi M, Li SS, Zheng C, Jones GJ, Kim KS, et al. (2010) Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest 120: 1683-1693.
19. Pai MP, Sakoglu U, Peterson SL, Lyons CR, Sood R, (2009) Characterization of BBB permeability in a preclinical model of cryptococcal meningoencephalitis using magnetic resonance imaging. J Cereb Blood Flow Metab 29: 545-553.
20. Olszewski MA, Noverr MC, Chen GH, Toews GB, Cox GM, et al. (2004) Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol 164: 1761-1771.
21. Stie J, Fox D, (2012) Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin. Microbiology 158: 240-258.
22. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL, (1995) The cell biology of the plasminogen system. FASEB J 9: 939-945.
23. Miles LA, Hawley SB, Baik N, Andronicos NM, Castellino FJ, et al. (2005) Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front Biosci 10: 1754-1762.
24. van H V, Engelse MA, Quax PH, (2006) Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 26: 716-728.
25. Kenny S, Duval C, Sammut SJ, Steele I, Pritchard DM, et al. (2008) Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 295: G431-G441.
26. Grab DJ, Perides G, Dumler JS, Kim KJ, Park J, et al. (2005) Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier. Infect Immun 73: 1014-1022.
27. Robbins KC, Summaria L, Hsieh B, Shah RJ, (1967) The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 242: 2333-2342.
28. Kasai S, Arimura H, Nishida M, Suyama T, (1985) Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 260: 12377-12381.
29. Stepanova VV, Tkachuk VA, (2002) Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry (Mosc) 67: 109-118.
30. Herren T, Swaisgood C, Plow EF, (2003) Regulation of plasminogen receptors. Front Biosci 8: d1-d8.
31. Nogueira SV, Fonseca FL, Rodrigues ML, Mundodi V, Bi-Chacra EA, et al. (2010) Paracoccidioides brasiliensis enolase is a surface protein that binds plasminogen and mediates interaction of yeast forms with host cells. Infect Immun 78: 4040-4050.
32. Stie J, Bruni G, Fox D, (2009) Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion. PLoS ONE 4: e5780.
33. Jong AY, Chen SH, Stins MF, Kim KS, Tuan TL, et al. (2003) Binding of Candida albicans enolase to plasmin(ogen) results in enhanced invasion of human brain microvascular endothelial cells. J Med Microbiol 52: 615-622.
34. Crowe JD, Sievwright IK, Auld GC, Moore NR, Gow NA, et al. (2003) Candida albicans binds human plasminogen: identification of eight plasminogen-binding proteins. Mol Microbiol 47: 1637-1651.
35. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, et al. (2004) Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305: 1283-1286.
36. Sebbane F, Jarrett CO, Gardner D, Long D, Hinnebusch BJ, (2006) Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague. Proc Natl Acad Sci U S A 103: 5526-5530.
37. Lathem WW, Price PA, Miller VL, Goldman WE, (2007) A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 315: 509-513.
38. Gotz JM, Vergouwe Y, Verspaget HW, Biemond I, Sier CF, et al. (1996) Gastric mucosal plasminogen activators in Helicobacter pylori infection. Dig Dis Sci 41: 1577-1582.
39. Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, et al. (1996) Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest 97: 1818-1826.
40. Gyetko MR, Sud S, Chen GH, Fuller JA, Chensue SW, et al. (2002) Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection. J Immunol 168: 801-809.
41. Litvintseva AP, Mitchell TG, (2009) Most environmental isolates of Cryptococcus neoformans var. grubii (serotype A) are not lethal for mice. Infect Immun 77: 3188-3195.
42. Stoppelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing VJ, et al. (1986) Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45: 675-684.
43. Niedbala MJ, Stein-Picarella M, (1992) Tumor necrosis factor regulation of endothelial cell extracellular proteolysis: the role of urokinase plasminogen activator. Biol Chem Hoppe Seyler 373: 555-566.
44. Granelli-Piperno A, Reich E, (1978) A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 148: 223-234.
45. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12: 1197-1205.
46. von Offenberg Sweeney N, Cummins PM, Cotter EJ, Fitzpatrick PA, Birney YA, et al. (2005) Cyclic strain-mediated regulation of vascular endothelial cell migration and tube formation. Biochem Biophys Res Commun 329: 573-582.
47. Pedersen CD, Fang JJ, Pedersen AE, (2009) A comparative study of transfection methods for RNA interference in bone marrow-derived murine dendritic cells. Scand J Immunol 70: 447-456.
48. Dussault AA, Pouliot M, (2006) Rapid and simple comparison of messenger RNA levels using real-time PCR. Biol Proced Online 8: 1-10.
49. Kornblau SM, Womble M, Cade JS, Lemker E, Qiu YH, (2005) Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia. Leukemia 19: 1550-1557.
50. Sier CF, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJ, et al. (1993) Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 34: 80-85.
51. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, et al. (1997) High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 79: 878-883.
52. Binder BR, Mihaly J, Prager GW, (2007) uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 97: 336-342.
53. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, et al. (1986) Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 5: 2539-2544.
54. Andolfo A, English WR, Resnati M, Murphy G, Blasi F, et al. (2002) Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost 88: 298-306.
55. Chavakis T, Willuweit AK, Lupu F, Preissner KT, Kanse SM, (2001) Release of soluble urokinase receptor from vascular cells. Thromb Haemost 86: 686-693.
56. Schiller HB, Szekeres A, Binder BR, Stockinger H, Leksa V, (2009) Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. Mol Biol Cell 20: 745-756.
57. Lijnen HR, Collen D, (1995) Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol 8: 277-290.
58. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y, (1999) The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56: 104-132.
59. Pepper MS, (2001) Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21: 1104-1117.
60. Abraham E, (2000) Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 22: 401-404.
61. Altus MS, Nagamine Y, (1991) Protein synthesis inhibition stabilizes urokinase-type plasminogen activator mRNA. Studies in vivo and in cell-free decay reactions. J Biol Chem 266: 21190-21196.
62. Henderson BR, Tansey WP, Phillips SM, Ramshaw IA, Kefford RF, (1992) Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Cancer Res 52: 2489-2496.
63. Shetty S, (2005) Protein synthesis and urokinase mRNA metabolism. Mol Cell Biochem 271: 13-22.
64. Nanbu R, Menoud PA, Nagamine Y, (1994) Multiple instability-regulating sites in the 3′ untranslated region of the urokinase-type plasminogen activator mRNA. Mol Cell Biol 14: 4920-4928.
65. Nanbu R, Montero L, D'Orazio D, Nagamine Y, (1997) Enhanced stability of urokinase-type plasminogen activator mRNA in metastatic breast cancer MDA-MB-231 cells and LLC-PK1 cells down-regulated for protein kinase C-correlation with cytoplasmic heterogeneous nuclear ribonucleoprotein C. Eur J Biochem 247: 169-174.
66. Nagamine Y, Medcalf RL, Munoz-Canoves P, (2005) Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost 93: 661-675.
67. Wu SQ, Aird WC, (2005) Thrombin, TNF-alpha, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 289: H873-H885.
68. Ohta S, Niiya K, Sakuragawa N, Fuse H, (2000) Induction of urokinase-type plasminogen activator by lipopolysaccharide in PC-3 human prostatic cancer cells. Thromb Res 97: 343-347.
69. Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Ohtsubo T, et al. (2005) Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori. Scand J Gastroenterol 40: 783-793.
70. Iozzo RV, (1985) Proteoglycans: structure, function, and role in neoplasia. Lab Invest 53: 373-396.
71. Horton MR, Olman MA, Bao C, White KE, Choi AM, et al. (2000) Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages. Am J Physiol Lung Cell Mol Physiol 279: L707-L715.
72. Kobayashi H, Suzuki M, Kanayama N, Nishida T, Takigawa M, et al. (2002) CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells. Int J Cancer 102: 379-389.
73. Ibrahim AS, Filler SG, Alcouloumre MS, Kozel TR, Edwards JE Jr, et al. (1995) Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsule. Infect Immun 63: 4368-4374.
74. Jong A, Wu CH, Zhou W, Chen HM, Huang SH, (2008) Infectomic analysis of gene expression profiles of human brain microvascular endothelial cells infected with Cryptococcus neoformans. J Biomed Biotechnol 2008: 375620.
75. Lopes Bezerra LM, Filler SG, (2004) Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury, and stimulation of tissue factor activity. Blood 103: 2143-2149.
76. Muthukrishnan L, Warder E, McNeil PL, (1991) Basic fibroblast growth factor is efficiently released from a cytosolic storage site through plasma membrane disruptions of endothelial cells. J Cell Physiol 148: 1-16.
77. McNeil PL, Muthukrishnan L, Warder E, D'Amore PA, (1989) Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 109: 811-822.
78. Li T, Jiang S, (2010) Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator. Pharm Biol 48: 161-165.
79. Bastaki M, Nelli EE, Dell'Era P, Rusnati M, Molinari-Tosatti MP, et al. (1997) Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Arterioscler Thromb Vasc Biol 17: 454-464.
80. Lee KH, Kim JR, (2009) Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor. Exp Mol Med 41: 180-188.
81. Kim TS, Sa SJ, Shin MY, Jang DM, Kwon SH, et al. (2009) Stimulation of plasminogen activator activity by free radicals in boar spermatozoa. Anim Reprod Sci 114: 228-237.
82. Kim TS, Kwon EH, Kim SU, Choi HS, Lim HJ, et al. (2010) Activation and expression of urokinase-type plasminogen activator are modulated by freezing/thawing process through activation of redox signal pathway in primary porcine endometrial cells. Cryobiology 60: 211-216.
83. Lee KH, Kim SW, Kim JR, (2009) Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells. J Exp Clin Cancer Res 28: 73.
84. Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z, et al. (2008) Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 27: 1273-1280.
85. Faisal A, Kleiner S, Nagamine Y, (2004) Non-redundant role of Shc in Erk activation by cytoskeletal reorganization. J Biol Chem 279: 3202-3211.
86. Hall CJ, Bouhafs L, Dizcfalusy U, Sandstedt K, (2010) Cryptococcus neoformans causes lipid peroxidation; therefore it is a potential inducer of atherogenesis. Mycologia 102: 546-551.
87. Qureshi A, Subathra M, Grey A, Schey K, Del Poeta M, et al. (2010) Role of sphingomyelin synthase in controlling the antimicrobial activity of neutrophils against Cryptococcus neoformans. PLoS ONE 5: e15587.